Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | OAT | P04181 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670621 | 0.87 | — | — | |
| SCHEMBL420637 | 0.87 | — | — | |
| SCHEMBL30484837 | 0.87 | — | — | |
| SCHEMBL56195 | 0.87 | — | — | |
| SCHEMBL7738881 | 0.87 | — | — | |
| SCHEMBL85607 | 0.87 | — | — | |
| SCHEMBL2562267 | 0.87 | — | — | |
| SCHEMBL5346790 | 0.87 | — | — | |
| SCHEMBL578646 | 0.87 | — | — | |
| SCHEMBL420636 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3114128-B1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-9233978-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252057-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2D6 | GABRR1 1697/4885PEPD 666/4885OAT 794/4885 |
| US-10428069-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, CYP2D6, CYP2B6 | GABRR1 1760/4885PEPD 520/4885OAT 579/4885 |
| US-20200062753-A1 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, CYP2D6, CYP2B6 | GABRR1 1760/4885PEPD 520/4885OAT 579/4885 |
| US-20180370969-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2D6 | GABRR1 1697/4885PEPD 666/4885OAT 794/4885 |
| US-10081627-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, CYP2D6, CYP2B6 | GABRR1 1760/4885PEPD 520/4885OAT 579/4885 |
| US-20160083383-A1 | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2D6 | GABRR1 1697/4885PEPD 666/4885OAT 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.